203 related articles for article (PubMed ID: 9823322)
1. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer.
Christianson TA; Doherty JK; Lin YJ; Ramsey EE; Holmes R; Keenan EJ; Clinton GM
Cancer Res; 1998 Nov; 58(22):5123-9. PubMed ID: 9823322
[TBL] [Abstract][Full Text] [Related]
2. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.
Molina MA; Sáez R; Ramsey EE; Garcia-Barchino MJ; Rojo F; Evans AJ; Albanell J; Keenan EJ; Lluch A; García-Conde J; Baselga J; Clinton GM
Clin Cancer Res; 2002 Feb; 8(2):347-53. PubMed ID: 11839648
[TBL] [Abstract][Full Text] [Related]
3. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of Ser78 of Hsp27 correlated with HER-2/neu status and lymph node positivity in breast cancer.
Zhang D; Wong LL; Koay ES
Mol Cancer; 2007 Aug; 6():52. PubMed ID: 17697330
[TBL] [Abstract][Full Text] [Related]
5. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
[TBL] [Abstract][Full Text] [Related]
6. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.
Sáez R; Molina MA; Ramsey EE; Rojo F; Keenan EJ; Albanell J; Lluch A; García-Conde J; Baselga J; Clinton GM
Clin Cancer Res; 2006 Jan; 12(2):424-31. PubMed ID: 16428482
[TBL] [Abstract][Full Text] [Related]
7. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
Hayes DF; Yamauchi H; Broadwater G; Cirrincione CT; Rodrigue SP; Berry DA; Younger J; Panasci LL; Millard F; Duggan DB; Norton L; Henderson IC;
Clin Cancer Res; 2001 Sep; 7(9):2703-11. PubMed ID: 11555582
[TBL] [Abstract][Full Text] [Related]
8. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
Bai T; Luoh SW
Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
[TBL] [Abstract][Full Text] [Related]
9. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
11. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
Witters L; Scherle P; Friedman S; Fridman J; Caulder E; Newton R; Lipton A
Cancer Res; 2008 Sep; 68(17):7083-9. PubMed ID: 18757423
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
[TBL] [Abstract][Full Text] [Related]
13. Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis.
Albanell J; Bellmunt J; Molina R; García M; Caragol I; Bermejo B; Ribas A; Carulla J; Gallego OS; Español T; Solé Calvo LA
Anticancer Res; 1996; 16(2):1027-32. PubMed ID: 8687094
[TBL] [Abstract][Full Text] [Related]
14. Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
Peredo R; Sastre G; Serrano J; Hunter Mellado R
Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1025-32. PubMed ID: 11785652
[TBL] [Abstract][Full Text] [Related]
15. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.
Bacus SS; Gudkov AV; Zelnick CR; Chin D; Stern R; Stancovski I; Peles E; Ben-Baruch N; Farbstein H; Lupu R
Cancer Res; 1993 Nov; 53(21):5251-61. PubMed ID: 8106145
[TBL] [Abstract][Full Text] [Related]
16. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R
Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine phosphorylation of PP2A is regulated by HER-2 signalling and correlates with breast cancer progression.
Wong LL; Chang CF; Koay ES; Zhang D
Int J Oncol; 2009 May; 34(5):1291-301. PubMed ID: 19360341
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
Esteva FJ; Sahin AA; Smith TL; Yang Y; Pusztai L; Nahta R; Buchholz TA; Buzdar AU; Hortobagyi GN; Bacus SS
Cancer; 2004 Feb; 100(3):499-506. PubMed ID: 14745865
[TBL] [Abstract][Full Text] [Related]
19. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
Pietras RJ; Fendly BM; Chazin VR; Pegram MD; Howell SB; Slamon DJ
Oncogene; 1994 Jul; 9(7):1829-38. PubMed ID: 7911565
[TBL] [Abstract][Full Text] [Related]
20. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.
Codony-Servat J; Albanell J; Lopez-Talavera JC; Arribas J; Baselga J
Cancer Res; 1999 Mar; 59(6):1196-201. PubMed ID: 10096547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
